Antibodies to synthetic peptides from the preS1 region of the hepatitis B virus (HBV) envelope (env) protein are virus-neutralizing and protective
- PMID: 2476893
- DOI: 10.1016/0264-410x(89)90235-1
Antibodies to synthetic peptides from the preS1 region of the hepatitis B virus (HBV) envelope (env) protein are virus-neutralizing and protective
Abstract
Hepatitis B virus (HBV) envelope (env) proteins contain three antigenic domains designated S, preS2 and preS1. Studies with synthetic peptide immunogens demonstrated the role of preS2 epitopes in protection against HBV infection. The preS1 domain is implicated in virus-cell receptor interactions suggesting that anti-preS1-specific antibodies should neutralize the infectivity of HBV by blocking virus attachment to cells. We present here evidence that an antiserum to a peptide from the preS1 sequence, anti-preS(21-47), is virus-neutralizing and that active immunization of chimpanzees with a longer peptide derived from the preS1 sequence, preS(12-47), elicits antibodies protective against HBV infection. These results establish the role of the preS1 domain in the process of virus neutralization and the potential of synthetic preS1 analogues for hepatitis B vaccination.
Similar articles
-
Hepatitis B virus surface antigen (HBsAg) as carrier for synthetic peptides having an attached hydrophobic tail.Mol Immunol. 1989 Jan;26(1):53-62. doi: 10.1016/0161-5890(89)90020-5. Mol Immunol. 1989. PMID: 2467197
-
Antibodies to synthetic peptides from the pre-S1 and pre-S2 regions of one subtype of the hepatitis B virus (HBV) envelope protein recognize all HBV subtypes.Mol Immunol. 1987 Sep;24(9):975-80. doi: 10.1016/0161-5890(87)90009-5. Mol Immunol. 1987. PMID: 3657811
-
Antibodies to a synthetic peptide from the preS 120-145 region of the hepatitis B virus envelope are virus neutralizing.Vaccine. 1986 Mar;4(1):35-7. doi: 10.1016/s0264-410x(86)80001-9. Vaccine. 1986. PMID: 2421497
-
Applications of human hepatitis B virus preS domain in bio- and nanotechnology.World J Gastroenterol. 2015 Jun 28;21(24):7400-11. doi: 10.3748/wjg.v21.i24.7400. World J Gastroenterol. 2015. PMID: 26139986 Free PMC article. Review.
-
Attachment sites and neutralising epitopes of hepatitis B virus.Minerva Gastroenterol Dietol. 2006 Mar;52(1):3-21. Minerva Gastroenterol Dietol. 2006. PMID: 16554703 Review.
Cited by
-
Pathogenicity and virulence of Hepatitis B virus.Virulence. 2022 Dec;13(1):258-296. doi: 10.1080/21505594.2022.2028483. Virulence. 2022. PMID: 35100095 Free PMC article. Review.
-
Prophylactic vaccination against hepatitis B: achievements, challenges and perspectives.Med Microbiol Immunol. 2015 Feb;204(1):39-55. doi: 10.1007/s00430-014-0373-y. Epub 2014 Dec 19. Med Microbiol Immunol. 2015. PMID: 25523195 Review.
-
Inhibition of preS1-hepatocyte interaction by an array of recombinant human antibodies from naturally recovered individuals.Sci Rep. 2016 Feb 18;6:21240. doi: 10.1038/srep21240. Sci Rep. 2016. PMID: 26888694 Free PMC article.
-
PreS1 epitope recognition in newborns after vaccination with the third-generation Sci-B-Vac vaccine and their relation to the antibody response to hepatitis B surface antigen.Virol J. 2009 Jan 20;6:7. doi: 10.1186/1743-422X-6-7. Virol J. 2009. PMID: 19154574 Free PMC article. Clinical Trial.
-
A virus-like particle of the hepatitis B virus preS antigen elicits robust neutralizing antibodies and T cell responses in mice.Antiviral Res. 2018 Jan;149:48-57. doi: 10.1016/j.antiviral.2017.11.007. Epub 2017 Nov 10. Antiviral Res. 2018. PMID: 29129705 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases